Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)

An Open-Label, Single Arm Study of MK-8808 in Patients With Advanced CD20-Positive Follicular Lymphoma

This study will evaluate the safety, pharmacokinetics, and anti-tumor activity of MK-8808 in combination with cyclophosphamide, vincristine, and prednisolone (CVP), and as a single agent, for participants with B-lymphocyte antigen cluster of differentiation 20 (CD20)-positive follicular lymphoma who have had no prior chemotherapy. The primary study hypothesis is that MK-8808 will be safe and well tolerated in combination with CVP and as a single agent.

Study Overview

• Status: Terminated
• Conditions: Follicular Lymphoma
• Intervention / Treatment: Drug: cyclophosphamide; Drug: prednisolone; Drug: vincristine; Drug: MK-8808

Detailed Description

The study was terminated early by the Sponsor due to business reasons. All participants were discontinued from MK-8808 + CVP, but could continue to receive maintenance therapy with MabThera™ (rituximab) per standard of care.

• Study Type: Interventional
• Enrollment (Actual): 7
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria:

• Histological diagnosis of CD20-positive follicular lymphoma, Grade 1, 2, or 3a (World Health Organization [WHO] 2008 classification) based on an excisional or incisional lymph node biopsy or a bone marrow biopsy.
• Ann Arbor Stage III or IV disease.
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
• Life expectancy >3 months with no expected need of immediate intervention to treat life-threatening complications.
• Adequate organ function.
• Participants must agree to use an adequate method of contraception starting with the first dose of study drug through 12 months (for females) or 90 days (for males) after the last dose of study drug.

Exclusion criteria:

• Histological Grade 3b or with >50% diffuse architectural pattern.
• Circulating malignant cells >25,000/mm^3
• Presence or history of central nervous system (CNS) disease (either CNS lymphoma or lymphomatous meningitis).
• Prior treatment with chemotherapy, rituximab, any other anti-CD20 compound, or any other type of anti-cancer compounds.
• Radiotherapy within 2 months prior to Cycle 1 Day 1.
• Current participation or has participated in a study with an investigational compound within 30 days prior to Cycle 1 Day 1.
• Concomitant disease that requires continuous therapy with prednisone at doses >20 mg per day.
• Any medical contraindication for prednisolone as being dosed in the CVP regimen.
• Poorly controlled diabetes mellitus, as defined by institutional or local standards.
• Grade >2 peripheral neuropathy.

• Has one of the following:

  1. is human immunodeficiency virus (HIV)-positive
  2. is Hepatitis B surface antigen positive (HBsAg+) or is positive for antibodies to Hepatitis B core antigen (anti-HBcAg+)
  3. has antibodies to Hepatitis C virus

• Has one or more of the following:

  1. Active tuberculosis based on institutional diagnostic criteria and local practice guidelines.
  2. Evidence of a tuberculosis infection based on a chest X-ray (CXR) or computed tomography (CT) scan performed within 3 months of dosing.
  3. History of a tuberculosis infection.
• Major surgical procedure within 4 weeks prior to Cycle 1 Day 1.
• Regular use (including "recreational" use) of any illicit drugs or recent history (within the last year) of drug or alcohol abuse or dependence.
• Pregnant or breastfeeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: MK-8808 Combination Therapy; Participants received MK-8808 375 mg/m^2 intravenously (IV) + cyclophosphamide 750 mg/m^2 IV + vincristine 1.4 mg/m^2 IV (maximum dose of 2 mg IV) on Day 1 each cycle, plus prednisolone 40 mg/m^2, orally on Days 1 to 5 of each cycle for a maximum of 8 cycles. Participants receiving clinical benefit could remain on MK-8808 375 mg/m^2 IV starting 8 weeks after last dose of combination therapy, every 2 months for up to 2 years.

Drug: cyclophosphamide; Drug: prednisolone; Drug: vincristine; Drug: MK-8808

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy	An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.	From first dose of combination therapy up to 24 weeks
Number of Participants Experiencing Clinical and Laboratory AEs During MK-8808 Maintenance Therapy	An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.	From first dose of single agent MK-8808 up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Concentration (Cmax) of Plasma Levels of MK-8808 When Used in Combination With CVP	Cmax is a measure of the maximum concentration of the drug in the plasma as measured using plasma samples taken over specified time points.	Pre-dose and end of infusion in each 21-day cycle and at end of therapy visit (up to 24 weeks)
Cmax of Plasma Levels of MK-8808 During Single Agent Maintenance Therapy	Cmax is a measure of the maximum amount of drug in the plasma over time using samples taken at specified time points.	Predose and end of infusion in every other cycle and at end of therapy visit (up to 2 years)
Lowest Concentration (Ctrough) of Plasma Levels of MK-8808 When Used in Combination With CVP	Ctrough is a measure of the lowest level of drug in the plasma over time, using plasma samples collected at specified time points.	Pre-dose and end of infusion in each 21-day cycle and at end of therapy visit (up to 24 weeks)
Ctrough of Plasma Levels of MK-8808 When Used as Single Agent Maintenance	Ctrough is a measure of the lowest level of drug in the plasma over time, using plasma samples collected at specified time points.	Predose and end of infusion in every other cycle and at end of therapy visit (up to 2 years)
Clinical Response of Tumor to MK-8808/CVP Combination Therapy	The response of the tumor to MK-8808/CVP combination therapy was radiographically assessed using Response Criteria Evaluation in Solid Tumors (RECIST). Response categories of partial response (PR), complete resonse (CR), and uncomfirmed (CRu) central review.	Up to 2 years

Collaborators and Investigators

• Sponsor: Merck Sharp & Dohme LLC

Study record dates

Study Major Dates

• Study Start (Actual): August 19, 2011
• Primary Completion (Actual): December 1, 2014
• Study Completion (Actual): December 1, 2014

Study Registration Dates

• First Submitted: May 18, 2011
• First Submitted That Met QC Criteria: June 9, 2011
• First Posted (Estimate): June 10, 2011

Study Record Updates

• Last Update Posted (Actual): March 15, 2019
• Last Update Submitted That Met QC Criteria: February 28, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, Follicular; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Prednisolone; Cyclophosphamide; Vincristine
• Other Study ID Numbers: 8808-001; 2011-000386-13 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Study Data/Documents

1. CSR Synopsis Link